These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 27785772)

  • 81. A Systematic Review of Direct Cardiovascular Event Costs: An International Perspective.
    Ryder S; Fox K; Rane P; Armstrong N; Wei CY; Deshpande S; Stirk L; Qian Y; Kleijnen J
    Pharmacoeconomics; 2019 Jul; 37(7):895-919. PubMed ID: 30949988
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years.
    Borissov B; Urbich M; Georgieva B; Tsenov S; Villa G
    J Mark Access Health Policy; 2017; 5(1):1412753. PubMed ID: 29321830
    [No Abstract]   [Full Text] [Related]  

  • 83. A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapies.
    Wei CY; Quek RGW; Villa G; Gandra SR; Forbes CA; Ryder S; Armstrong N; Deshpande S; Duffy S; Kleijnen J; Lindgren P
    Pharmacoeconomics; 2017 Mar; 35(3):297-318. PubMed ID: 27785772
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation.
    Ara R; Pandor A; Stevens J; Rees A; Rafia R
    Health Technol Assess; 2009 Jul; 13(34):1-74, 75-118. PubMed ID: 19604457
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Improving adherence to lipid-lowering therapy in a community pharmacy intervention program: a cost-effectiveness analysis.
    Vegter S; Oosterhof P; van Boven JF; Stuurman-Bieze AG; Hiddink EG; Postma MJ
    J Manag Care Spec Pharm; 2014 Jul; 20(7):722-32. PubMed ID: 24967525
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation.
    Picot J; Jones J; Colquitt JL; Gospodarevskaya E; Loveman E; Baxter L; Clegg AJ
    Health Technol Assess; 2009 Sep; 13(41):1-190, 215-357, iii-iv. PubMed ID: 19726018
    [TBL] [Abstract][Full Text] [Related]  

  • 88. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).
    Piepoli MF; Hoes AW; Agewall S; Albus C; Brotons C; Catapano AL; Cooney MT; Corrà U; Cosyns B; Deaton C; Graham I; Hall MS; Hobbs FDR; Løchen ML; Löllgen H; Marques-Vidal P; Perk J; Prescott E; Redon J; Richter DJ; Sattar N; Smulders Y; Tiberi M; van der Worp HB; van Dis I; Verschuren WMM; Binno S;
    Eur Heart J; 2016 Aug; 37(29):2315-2381. PubMed ID: 27222591
    [No Abstract]   [Full Text] [Related]  

  • 89. Secondary prevention after PCI: the cost-effectiveness of statin therapy in the Netherlands.
    Chaplin S; Scuffham PA; Alon M; van den Boom G
    Neth Heart J; 2004 Aug; 12(7-8):331-336. PubMed ID: 25696357
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Cost-effectiveness of high, moderate and low-dose statins in the prevention of vascular events in the Brazilian public health system.
    Ribeiro RA; Duncan BB; Ziegelmann PK; Stella SF; Vieira JL; Restelatto LM; Polanczyk CA
    Arq Bras Cardiol; 2015 Jan; 104(1):32-44. PubMed ID: 25409878
    [TBL] [Abstract][Full Text] [Related]  

  • 91. A systematic review of economic evaluations of the detection and treatment of familial hypercholesterolemia.
    Ademi Z; Watts GF; Juniper A; Liew D
    Int J Cardiol; 2013 Sep; 167(6):2391-6. PubMed ID: 23490080
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Generic atorvastatin, the Belgian statin market and the cost-effectiveness of statin therapy.
    Simoens S; Sinnaeve PR
    Cardiovasc Drugs Ther; 2013 Feb; 27(1):49-60. PubMed ID: 23242669
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Statin cost effectiveness in primary prevention: a systematic review of the recent cost-effectiveness literature in the United States.
    Mitchell AP; Simpson RJ
    BMC Res Notes; 2012 Jul; 5():373. PubMed ID: 22828389
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Principles of health economic evaluations of lipid-lowering strategies.
    Ara R; Basarir H; Ward SE
    Curr Opin Lipidol; 2012 Aug; 23(4):271-81. PubMed ID: 22617753
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Impact of statin dose on major cardiovascular events: a mixed treatment comparison meta-analysis involving more than 175,000 patients.
    Ribeiro RA; Ziegelmann PK; Duncan BB; Stella SF; da Costa Vieira JL; Restelatto LM; Moriguchi EH; Polanczyk CA
    Int J Cardiol; 2013 Jun; 166(2):431-9. PubMed ID: 22192281
    [TBL] [Abstract][Full Text] [Related]  

  • 96.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.